DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Peramivir

Peramivir

  • Drug Name Peramivir Brand Name(S)

    Drug Name Peramivir Brand Name(S)

  • Influenza: Diagnosis and Treatment

    Influenza: Diagnosis and Treatment

  • Alpivab, INN-Peramivir

    Alpivab, INN-Peramivir

  • RAPIVAB (Peramivir) Injection, for Intravenous Use  See the Full Prescribing Information for Drug Compatibility Information Initial U.S

    RAPIVAB (Peramivir) Injection, for Intravenous Use  See the Full Prescribing Information for Drug Compatibility Information Initial U.S

  • Official Title: a Phase III, Randomized, Double-Blind Placebo-Controlled

    Official Title: a Phase III, Randomized, Double-Blind Placebo-Controlled

  • Peramivir (Rapivab®) National Drug Monograph March 2015

    Peramivir (Rapivab®) National Drug Monograph March 2015

  • In Vitro Activity of Favipiravir and Neuraminidase Inhibitor Combinations Against Oseltamivir-Sensitive and Oseltamivir-Resistant Pandemic Influenza a (H1N1) Virus

    In Vitro Activity of Favipiravir and Neuraminidase Inhibitor Combinations Against Oseltamivir-Sensitive and Oseltamivir-Resistant Pandemic Influenza a (H1N1) Virus

  • Q1 2018 Pharmacy & Therapeutics Committee

    Q1 2018 Pharmacy & Therapeutics Committee

  • 210854Orig1s000

    210854Orig1s000

  • Clinical Review Melisse Baylor, MD NDA 210854 Baloxavir Marboxil

    Clinical Review Melisse Baylor, MD NDA 210854 Baloxavir Marboxil

  • Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects

    Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects

  • Clinical Efficacy of New Neuraminidase Inhibitors, Laninamivir And

    Clinical Efficacy of New Neuraminidase Inhibitors, Laninamivir And

  • Peramivir Fact Sheet for Health Care Providers

    Peramivir Fact Sheet for Health Care Providers

  • Favipiravir in Therapy of Viral Infections

    Favipiravir in Therapy of Viral Infections

  • Optimizing Treatment

    Optimizing Treatment

  • Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act

    Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act

  • Peramivir Is an Intravenous Neuraminidase Inhibitor

    Peramivir Is an Intravenous Neuraminidase Inhibitor

  • Uses and Administration Adverse Effects Profile Profile Profile Uses

    Uses and Administration Adverse Effects Profile Profile Profile Uses

Top View
  • Therapeutic Class Overview Antivirals, Influenza
  • Potential Drug-Drug Interactions of Antiretrovirals and Antimicrobials
  • Antivirals Targeting the Surface Glycoproteins of Influenza Virus
  • Pandemic H1N1 'Swine Flu'
  • USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
  • 2019 Peramivir for Influenza a and B Viral Infections
  • Antivirals, Influenza
  • An HHS Retrospective on the 2009 H1N1 Influenza Pandemic to Advance All Hazards Preparedness
  • Antivirals, Influenza
  • Review Laninamivir and Its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
  • Assessment of Adverse Events Related to Anti-Influenza Neuraminidase
  • Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis
  • (H1N1) 2009 and Other Influenza Viruses
  • Assessment of Evidence for COVID-19-Related Treatments
  • Alpivab, INN-Peramivir
  • Influenza Antiviral Medications: Summary for Clinicians
  • RAPIVAB Safely and Effectively
  • Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal


© 2024 Docslib.org    Feedback